FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Kurilla

Research Profile

Living Beings

Chemicals & Drugs

Anatomy

Concepts & Ideas

Molecular Sequence Data

Genes & Molecular Sequences

Amino Acid Sequences

Physiology

Disorders

Herpesviridae Infections

Co-author Network

Publications

TOP 3
Ekaterina V Bobkova; Yong Ping Yan; Douglas Jordan; Michael Kurilla; David L Pompliano
Catalytic properties of mutant 23 S ribosomes resistant to oxazolidinones.
Maria D F S Barbosa; Siqi Lin; Jay A Markwalder; Jonathan A Mills; Joseph A DeVito; Christopher A Teleha; Vasudha Garlapati; Charles Liu; Andy Thompson; George L Trainor; Michael Kurilla; David L Pompliano
Regulated expression of the Escherichia coli lepB gene as a tool for cellular testing of antimicrobial compounds that inhibit signal peptidase I in vitro.
Maria D F S Barbosa; Harold O Ross; Milton C Hillman; Raymond P Meade; Michael Kurilla; David L Pompliano
A multitarget assay for inhibitors of membrane-associated steps of peptidoglycan biosynthesis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Kurilla (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2003: Ekaterina V Bobkova; Yong Ping Yan; Douglas Jordan; Michael Kurilla; David L Pompliano
Catalytic properties of mutant 23 S ribosomes resistant to oxazolidinones.
The Journal of biological chemistry 2003;278(11):9802-7.
2002: Maria D F S Barbosa; Siqi Lin; Jay A Markwalder; Jonathan A Mills; Joseph A DeVito; Christopher A Teleha; Vasudha Garlapati; Charles Liu; Andy Thompson; George L Trainor; Michael Kurilla; David L Pompliano
Regulated expression of the Escherichia coli lepB gene as a tool for cellular testing of antimicrobial compounds that inhibit signal peptidase I in vitro.
Antimicrobial agents and chemotherapy 2002;46(11):3549-54.
2002: Maria D F S Barbosa; Harold O Ross; Milton C Hillman; Raymond P Meade; Michael Kurilla; David L Pompliano
A multitarget assay for inhibitors of membrane-associated steps of peptidoglycan biosynthesis.
Analytical biochemistry 2002;306(1):17-22.
2002: Yi Zhang; Fude Yang; Yeh-Chih Kao; Michael Kurilla; David L Pompliano; ira dicker
Homogenous assays for Escherichia coli DnaB-stimulated DnaG primase and DnaB helicase and their use in screening for chemical inhibitors.
Analytical biochemistry 2002;304(2):174-9.
2002: Fude Yang; ira dicker; Michael Kurilla; David L Pompliano
PolC-type polymerase III of Streptococcus pyogenes and its use in screening for chemical inhibitors.
Analytical biochemistry 2002;304(1):110-6.
2002: Maria D F S Barbosa; Gaoyun Yang; Jie Fang; Michael Kurilla; David L Pompliano
Development of a whole-cell assay for peptidoglycan biosynthesis inhibitors.
Antimicrobial agents and chemotherapy 2002;46(4):943-6.
2001: U Patel; Yong Ping Yan; F W Hobbs; J Kaczmarczyk; AM Slee; David L Pompliano; Michael Kurilla; Ekaterina V Bobkova
Oxazolidinones mechanism of action: inhibition of the first peptide bond formation.
The Journal of biological chemistry 2001;276(40):37199-205.
2001: J Liu; P A Feldman; J S Lippy; Ekaterina V Bobkova; Michael Kurilla; T D Chung
A scintillation proximity assay for rna detection.
Analytical biochemistry 2001;289(2):239-45.
2000: PM Steigerwald-Mullen; Michael Kurilla; Thomas J Braciale
Type 2 cytokines predominate in the human CD4(+) T-lymphocyte response to Epstein-Barr virus nuclear antigen 1.
Journal of virology 2000;74(15):6748-59.
2000: Christian Münz; Kara Bickham; Marion Subklewe; Ming L Tsang; A Chahroudi; Michael Kurilla; D Zhang; Mike O'Donnell; Ralph M Steinman
Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
The Journal of experimental medicine 2000;191(10):1649-60.
2000: Xia Jin; MA Demoitie; Sean M Donahoe; Graham S Ogg; Sebastian Bonhoeffer; WM Kakimoto; G Gillespie; P A Moss; W Dyer; Michael Kurilla; S R Riddell; J Downie; John Sullivan; Andrew J McMichael; C Workman; Douglas F Nixon
High frequency of cytomegalovirus-specific cytotoxic T-effector cells in HLA-A*0201-positive subjects during multiple viral coinfections.
The Journal of infectious diseases 2000;181(1):165-75.
1999: Marion Subklewe; A Chahroudi; Kara Bickham; Marie Larsson; Michael Kurilla; Nina Bhardwaj; Ralph M Steinman
Presentation of epstein-barr virus latency antigens to CD8(+), interferon-gamma-secreting, T lymphocytes.
European journal of immunology 1999;29(12):3995-4001.
1999: Marion Subklewe; A Chahroudi; Alan L Schmaljohn; Michael Kurilla; Nina Bhardwaj; Ralph M Steinman
Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus.
Blood 1999;94(4):1372-81.
1998: Donna J Webb; J Wen; LR Karns; Michael Kurilla; Steven L Gonias
Localization of the binding site for transforming growth factor-beta in human alpha2-macroglobulin to a 20-kDa peptide that also contains the bait region.
The Journal of biological chemistry 1998;273(21):13339-46.
1997: Victor Levitsky; Q J Zhang; Jelena Levitskaya; Michael Kurilla; Maria Masucci
Natural variants of the immunodominant HLA A11-restricted CTL epitope of the EBV nuclear antigen-4 are nonimmunogenic due to intracellular dissociation from MHC class I:peptide complexes.
Journal of immunology (Baltimore, Md. : 1950) 1997;159(11):5383-90.
1997: Neil Blake; S Lee; IV Redchenko; W Thomas; Neil M Steven; Alison M Leese; PM Steigerwald-Mullen; Michael Kurilla; L Frappier; Alan B Rickinson
Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing.
Immunity 1997;7(6):791-802.
1997: Rajiv Khanna; Scott R Burrows; PM Steigerwald-Mullen; Denis Moss; Michael Kurilla; L Cooper
Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing.
International immunology 1997;9(10):1537-43.
1997: Y Shi; KD Smith; Michael Kurilla; Charles T Lutz
Cytotoxic CD8+ T cells recognize EBV antigen but poorly kill autologous EBV-infected B lymphoblasts: immunodominance is elicited by a peptide epitope that is presented at low levels in vitro.
Journal of immunology (Baltimore, Md. : 1950) 1997;159(4):1844-52.
1997: Neil M Steven; Nicola E Annels; A Kumar; Alison M Leese; Michael Kurilla; Alan B Rickinson
Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response.
The Journal of experimental medicine 1997;185(9):1605-17.
1997: Michael Kurilla
Transient selection during vaccinia virus recombination with insertion vectors without selectable markers.
BioTechniques 1997;22(5):906-10.
1996: Teresa Frisan; Q J Zhang; Jelena Levitskaya; M Coram; Michael Kurilla; Maria Masucci
Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells.
International journal of cancer. Journal international du cancer 1996;68(2):251-8.
1996: C A White; SM Cross; Michael Kurilla; B M Kerr; C Schmidt; Ihor Misko; Rajiv Khanna; Denis Moss
Recruitment during infectious mononucleosis of CD3+CD4+CD8+ virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1.
Virology 1996;219(2):489-92.
1995: Rajiv Khanna; Scott R Burrows; P M Steigerwald-Mullen; Scott A Thomson; Michael Kurilla; Denis Moss
Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance.
Virology 1995;214(2):633-7.
1995: Jelena Levitskaya; M Coram; Victor Levitsky; S Imreh; P M Steigerwald-Mullen; George Klein; Michael Kurilla; Maria Masucci
Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.
Nature 1995;375(6533):685-8.
1995: Michael Kurilla; T Heineman; L C Davenport; E Kieff; L M Hutt-Fletcher
A novel Epstein-Barr virus glycoprotein gp150 expressed from the BDLF3 open reading frame.
Virology 1995;209(1):108-21.
1994: V P Argaet; Christopher W Schmidt; Scott R Burrows; Sharon L Silins; Michael Kurilla; D L Doolan; Andreas Suhrbier; Denis Moss; Elliott Kieff; Tom Sculley; Ihor Misko
Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus.
The Journal of experimental medicine 1994;180(6):2335-40.
1993: Michael Kurilla; S Swaminathan; Raymond M Welsh; E Kieff; R R Brutkiewicz
Effects of virally expressed interleukin-10 on vaccinia virus infection in mice.
Journal of virology 1993;67(12):7623-8.
1993: Steven P Lee; Wendy A Thomas; R J Murray; Farhat L Khanim; S Kaur; Lawrence S Young; Martin Rowe; Michael Kurilla; Alan B Rickinson
HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
Journal of virology 1993;67(12):7428-35.
1993: Jill M Brooks; R J Murray; Wendy A Thomas; Michael Kurilla; Alan B Rickinson
Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide.
The Journal of experimental medicine 1993;178(3):879-87.
1993: Riccardo Gavioli; Michael Kurilla; P O de Campos-Lima; L E Wallace; Riccardo Dolcetti; R J Murray; Alan B Rickinson; Maria Masucci
Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4.
Journal of virology 1993;67(3):1572-8.
1992: A L Lear; Martin Rowe; Michael Kurilla; S Lee; S Henderson; Elliott Kieff; Alan B Rickinson
The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.
Journal of virology 1992;66(12):7461-8.
1992: Rajiv Khanna; Scott R Burrows; Michael Kurilla; C A Jacob; Ihor Misko; Tom Sculley; Elliott Kieff; Denis Moss
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
The Journal of experimental medicine 1992;176(1):169-76.
1992: Riccardo Gavioli; P O De Campos-Lima; Michael Kurilla; Elliott Kieff; George Klein; Maria Masucci
Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(13):5862-6.
1992: R J Murray; Michael Kurilla; Jill M Brooks; Wendy A Thomas; Martin Rowe; Elliott Kieff; Alan B Rickinson
Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
The Journal of experimental medicine 1992;176(1):157-68.
1991: Rajiv Khanna; C A Jacob; Scott R Burrows; Michael Kurilla; Elliott Kieff; Ihor Misko; Tom Sculley; Denis Moss
Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells.
Immunology 1991;74(3):504-10.
1990: R J Murray; Michael Kurilla; H M Griffin; Jill M Brooks; M Mackett; J R Arrand; Martin Rowe; Scott R Burrows; Denis Moss; Elliott Kieff
Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(8):2906-10.